Keros Therapeutics is focused on developing innovative therapies that target the transforming growth factor-beta (TGF-β) superfamily of proteins, which play a crucial role in various biological processes, including tissue development and homeostasis. The company is leveraging its expertise in protein engineering and drug development to create novel therapeutics aimed at modulating TGF-β signaling. Their pipeline includes product candidates such as KER-050, which is designed to treat hematological disorders like myelodysplastic syndromes and myelofibrosis by inhibiting activin A to restore normal blood cell production. KER-012 is another candidate targeting pulmonary arterial hypertension (PAH) and cardiovascular disorders, aiming to enhance BMP signaling and address the underlying disease pathology rather than just alleviating symptoms.

In addition to hematological and cardiovascular applications, Keros is also developing KER-065 for obesity and neuromuscular disorders. This candidate has shown promise in preclinical studies for increasing skeletal muscle mass and reducing fat, potentially improving insulin sensitivity and cardiac function. KER-065 is particularly relevant for conditions like Duchenne muscular dystrophy, where it may help counteract muscle degeneration and improve overall health outcomes. Keros Therapeutics is committed to advancing these investigational therapies through rigorous clinical trials to address significant unmet medical needs in these patient populations.

United States

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from rare hematologic and musculoskeletal disorders with high unmet medical need.

Musculoskeletal Diseases

Nervous System Diseases

Keros Therapeutics

Blood disorder

Cancer

Myelodysplastic syndrome

Keros' lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.
<a href="https://www.kerostx.com/our-leads">Source&nbsp;</a>

KER-050 (elritercept)

Blood cancer

Cystic fibrosis

Lung disease

Myelofibrosis

Keros’ lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.
<a href="https://www.kerostx.com/our-leads">Source</a>

Duchenne muscular dystrophy

Neuromuscular disease

KER-065

Obesity

Anemia

Fibrodysplasia ossificans progressiva

Keros' lead small molecule product candidate, KER-047, is designed to selectively and potently inhibit activin receptor-like kinase-2, or ALK2, a TGF-β receptor. We are developing KER-047 for the treatment of anemia resulting from iron imbalance, including iron deficiency anemia (IDA) and iron-refractory iron deficiency anemia (IRIDA). We are also developing KER-047 as a treatment for fibrodysplasia ossificans progressiva, or FOP, a rare genetic disease resulting from activating mutations in the ALK2 receptor.
<a href="https://www.kerostx.com/our-leads">Source</a>

KER-047 (ALK2 inhibitor) 

Cardiovascular disease

Pulmonary hypertension

KER-012 is designed to bind to and inhibit the signaling of TGF-ß &nbsp;ligands that suppress bone growth, including activin A and activin B. &nbsp;Keros believes that KER-012 has the potential to increase the signaling &nbsp;of BMP pathways through this inhibition of activin A and activin B &nbsp;signaling, and consequently treat diseases such as PAH that are &nbsp;associated with reduced BMP signaling due to inactivating mutations in &nbsp;the BMP receptors. KER-012 is being developed for the treatment of PAH &nbsp;and for the treatment of disorders associated with bone loss, such as &nbsp;osteogenesis imperfecta and osteoporosis.

KER-012 (cibotercept)

Keros' lead small molecule product candidate, KER-047, is designed to selectively and potently inhibit activin receptor-like kinase-2, or ALK2, a TGF-β receptor.&nbsp;
<a href="https://www.kerostx.com/our-leads">Source</a>

Keros Therapeutics

Company Details